This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 24/10/1904    most recent 01.ATV.0000142808.34602.25v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Choudhury, R. P. Articles by Fisher, E. A. Search for Related Content PubMed PubMed Citation Articles by Choudhury, R. P. Articles by Fisher, E. A. Related Collections Other arteriosclerosis Genetically altered mice Lipid and lipoprotein metabolism Mechanism of atherosclerosis/growth factors

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1904.)
© 2004 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

High-Density Lipoproteins Retard the Progression of Atherosclerosis and Favorably Remodel Lesions Without Suppressing Indices of Inflammation or Oxidation

Robin P. Choudhury; James X. Rong; Eugene Trogan; Valerie I. Elmalem; Hayes M. Dansky; Jan L. Breslow; Joseph L. Witztum; John T. Fallon; Edward A. Fisher

From the Departments of Medicine (R.P.C., J.X.R., E.T., V.I.E., H.M.D., J.T.F., E.A.F.), Marc and Ruti Bell Program in Vascular Biology in the Leon H. Charney Division of Cardiology, and Cell Biology, New York University School of Medicine and Department of Medicine and The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York; the Laboratory of Biochemical Genetics and Human Metabolism (J.L.B.), Rockefeller University, New York; and the Department of Medicine (J.L.W.), University of California San Diego, La Jolla, Calif.

Correspondence to Edward A. Fisher, New York University School of Medicine, TH-451, 550 First Avenue, New York, NY 10016. E-mail edward.fisher{at}med.nyu.edu

Objective— Protective properties of high-density lipoproteins (HDL) may include reverse cholesterol transport and suppression of oxidation and inflammation. These were investigated in vivo, as were the effects of HDL on the characteristics of atherosclerotic lesions.

Methods and Results— Male apolipoprotein E knockout (apoE–/–) and apoE–/– mice expressing human apolipoprotein AI (hAI/apoE–/–) were studied up to 20 weeks after commencing a high-fat diet. Plasma HDL cholesterol was twice as high in hAI/apoE–/– mice. Over time, aortic root lesion area remained less in hAI/apoE–/– mice, although plaques became complex. In advanced lesions, plaque lipid was higher in apoE–/– mice, whereas plaque collagen and alpha actin were increased in hAI/apoE–/– mice. In nonlesional aorta, mRNA abundance for pro-inflammatory proteins (vascular cell adhesion molecule [VCAM]-1, intercellular adhesion molecule-1 [ICAM-1], monocyte chemoattractant protein-1 [MCP-1]) increased between 4 and 16 weeks in apoE–/– (but not wild-type) mice, and were not reduced by elevated HDL. Autoantibodies to malondialdehyde low-density lipoprotein (LDL) increased progressively in apoE–/– mice, with similar results in hAI/apoE–/– mice.

Conclusions— HDL retarded plaque size progression despite greatly elevated plasma cholesterol. This effect was over a wide range of lesion severity. Expression of hAI reduced plaque lipid and increased the proportion of plaque occupied by collagen and smooth muscle cells, but did not affect indicators of inflammation or LDL oxidation.

We have studied the progression of atherosclerosis in male apoE–/– and hAI/apoE–/– mice fed a Western diet. Elevation of HDL retarded the size progression of atherosclerosis, reduced plaque lipid content, and increased plaque collagen, despite greatly elevated non-HDL cholesterol. These changes occurred without evidence of reduced aortic inflammation or LDL oxidation.

Key Words: high-density lipoproteins • mice • atherosclerosis • inflammation

This article has been cited by other articles:

				J. M S Lee and R. P Choudhury Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets Heart, May 1, 2007; 93(5): 559 - 564. [Abstract] [Full Text] [PDF]

				A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]

				E. Trogan, J. E. Feig, S. Dogan, G. H. Rothblat, V. Angeli, F. Tacke, G. J. Randolph, and E. A. Fisher Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. PNAS, March 7, 2006; 103(10): 3781 - 3786. [Abstract] [Full Text] [PDF]

				D. Seetharam, C. Mineo, A. K. Gormley, L. L. Gibson, W. Vongpatanasin, K. L. Chambliss, L. D. Hahner, M. L. Cummings, R. L. Kitchens, Y. L. Marcel, et al. High-Density Lipoprotein Promotes Endothelial Cell Migration and Reendothelialization via Scavenger Receptor-B Type I Circ. Res., January 6, 2006; 98(1): 63 - 72. [Abstract] [Full Text] [PDF]

				P. J. Goldschmidt-Clermont, M. A. Creager, D. W. Lorsordo, G. K.W. Lam, M. Wassef, and V. J. Dzau Atherosclerosis 2005: Recent Discoveries and Novel Hypotheses Circulation, November 22, 2005; 112(21): 3348 - 3353. [Full Text] [PDF]

				J. M. Lee and R. P Choudhury ARBITER 2: targeting HDL to retard atherosclerosis progression: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2 The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 78 - 80. [PDF]